ライフサイエンスコーパス: leukemia inhibitory factor

1 tor, vascular endothelial growth factor, and leukemia inhibitory factor).

2 g conditions, specifically in the absence of leukemia inhibitory factor.

3 B activation of E-cadherin was responsive to leukemia inhibitory factor.

4 cts of sweat gland-containing footpads or by leukemia inhibitory factor.

5 K2 induced by GH but not interferon-gamma or leukemia inhibitory factor.

6 onists like endothelin-1, phenylephrine, and leukemia inhibitory factor.

7 of the IL-6-type cytokines, IL-6, IL-11, and leukemia inhibitory factor.

8 sufficient to induce both interleukin-6 and leukemia inhibitory factor.

9 ptin sustains pluripotency in the absence of leukemia inhibitory factor.

10 L-17, increasing production of IFN-gamma and leukemia inhibitory factor.

11 f-renewal to differentiation upon removal of leukemia inhibitory factor.

12 , including interleukin 6, oncostatin M, and leukemia inhibitory factor.

13 ertrophic agonists such as phenylephrine and leukemia inhibitory factor.

14 s in the absence of feeder cells, serum, and leukemia inhibitory factor.

15 IL-6, IL-8, cyclooxygenase 1 (COX-1), COX-2, leukemia inhibitory factor 1, transforming growth factor

16 On this background, T3, NE, and leukemia inhibitory factor activate hypertrophy with dif

17 y, including ciliary neurotrophic factor and leukemia inhibitory factor, also cause a transient initi

18 ytokine receptor gp130 and the receptors for leukemia inhibitory factor and granulocyte colony-stimul

19 weeks in stromal cultures in the presence of leukemia inhibitory factor and IL-6.

20 ix production but opposite effects regarding leukemia inhibitory factor and insulin-like growth facto

21 -F442A fibroblasts with growth hormone (GH), leukemia inhibitory factor and interferon-gamma.

22 ses to other gp130-signaling cytokines (e.g. leukemia inhibitory factor and interleukin 11).

23 potency of mouse ES cells requires both LIF (leukemia inhibitory factor) and unknown factors in serum

24 newal of pluripotent cells in the absence of leukemia inhibitory factor, and directly regulated mouse

25 ctor-alpha, transforming growth factor-beta, leukemia inhibitory factor, and IL-11 did not increase b

26 amily cytokines ciliary neurotrophic factor, leukemia inhibitory factor, and IL-11 have been identifi

27 actors, such as ciliary neurotrophic factor, leukemia inhibitory factor, and insulin, that are essent

28 de IL-6, IL-11, ciliary neurotrophic factor, leukemia inhibitory factor, and oncostatin M (OSM).

29 -JAK/STAT3 signaling pathway, interleukin-6, leukemia inhibitory factor, and oncostatin M were elevat

30 hat stimulate megakaryopoiesis (IL-6, IL-11, leukemia inhibitory factor, and oncostatin M) bind to re

31 rative factors insulin-like growth factor 1, leukemia inhibitory factor, and urokinase-type plasminog

32 mbryonic stem cells by fibronectin, laminin, leukemia-inhibitory factor, and fibroblast growth factor

33 in Q344ter mice was slowed by Axokine and by leukemia inhibitory factor; and the degeneration in a fe

34 Oncostatin M (OSM) and leukemia inhibitory factor are pleiotropic cytokines tha

35 both by the induction of an "injury factor," leukemia inhibitory factor, as shown previously, and by

36 c factor (CNTF), Axokine (a mutein of CNTF), leukemia inhibitory factor, basic fibroblast growth fact

37 , application of factors that activate gp130/leukemia inhibitory factor beta (LIFbeta) heterodimeric

38 Notably, leukemia inhibitory factor, but not interferon-gamma, al

39 n of the differentiation-associated cytokine leukemia inhibitory factor by atopic fibroblasts.

40 eral sclerosis) and influences on longevity (leukemia inhibitory factor, ceramides).

41 s containing interleukin-3 (IL-3), IL-6, and leukemia inhibitory factor contained a mean of 75% of un

42 rs of the ciliary neurotrophic factor (CNTF)-leukemia inhibitory factor cytokine family regulate glio

43 HepG2 cells stimulated with oncostatin M or leukemia inhibitory factor, cytokines which also use gp1

44 Here we report the production of leukemia inhibitory factor-dependent, so-called naive ty

45 Supplementation of KM with leukemia inhibitory factor elicited lineage restriction

46 In contrast, leukemia inhibitory factor fails to activate Akt or prom

47 of differentiation through the withdrawal of leukemia-inhibitory factor for 6 or more days.

48 n vitro differentiation following removal of leukemia inhibitory factor from the growth media.

49 ment increased m(6)A methylation in the LIF (Leukemia Inhibitory Factor) gene and decreased LIF mRNA

50 lia can stably self-renew in the presence of leukemia inhibitory factor, GSK3 inhibitor (CHIR99021),

51 Leukemia inhibitory factor has been utilized to maintain

52 layers in the presence of human recombinant leukemia inhibitory factor, human recombinant basic fibr

53 ardiotrophin-like cytokine factor 1 (CLCF1), leukemia inhibitory factor, IL-27, and IL-6.

54 not proliferate in the absence of exogenous leukemia inhibitory factor in an in vitro methylcellulos

55 sulin-like growth factor (IGF)-1, IGF-2, and leukemia inhibitory factor in medulloblastoma cells, but

56 n osteoblasts, also induce interleukin-6 and leukemia inhibitory factor in these cells.

57 he cytokines ciliary neurotrophic factor and leukemia inhibitory factor increases expression of endog

58 (NE) through a beta-adrenergic receptor, and leukemia inhibitory factor induced hypertrophy by a 20%

59 e of its soluble receptor), but not IL-1 nor leukemia inhibitory factor, induced Akt phosphorylation

60 le collagens, matrix metalloproteinases, and leukemia inhibitory factor, insulin-like growth factor 1

61 In response to GH and leukemia inhibitory factor, IRS-2 is immediately phospho

62 d transient stimulation of interleukin-6 and leukemia inhibitory factor is inhibited by actinomycin D

63 , but in some experiments minor increases in leukemia inhibitory factor levels were observed.

64 We identify tumor produced IL-1alpha and leukemia inhibitory factor (LIF) acting on splenic HSPCs

65 Cortical progenitors begin to interpret leukemia inhibitory factor (LIF) and bone morphogenetic

66 d underlying signal transduction pathways of leukemia inhibitory factor (LIF) and bone-morphogenic pr

67 The CDFs leukemia inhibitory factor (LIF) and ciliary neurotrophi

68 Our data indicate that leukemia inhibitory factor (LIF) and ciliary neurotrophi

69 ranscription factor pathway are activated by leukemia inhibitory factor (LIF) and contribute to mouse

70 Activation of the receptors for leukemia inhibitory factor (LIF) and IL-11 is essential

71 unts of the IL-6 family cytokines, including Leukemia inhibitory factor (LIF) and Interleukin 6 (IL-6

72 the expression of the neuropoietic cytokines leukemia inhibitory factor (LIF) and its receptor (LIFR)

73 Leukemia inhibitory factor (LIF) and LIF receptors are e

74 Leukemia inhibitory factor (LIF) and LIF receptors have

75 We have shown recently that leukemia inhibitory factor (LIF) and oncostatin M (OSM),

76 rferon (IFN), but retained responsiveness to leukemia inhibitory factor (LIF) and remained LIF depend

77 egulation of cell cycle-associated genes and leukemia inhibitory factor (Lif) and revealed alteration

78 te that cYes kinase activity is regulated by leukemia inhibitory factor (LIF) and serum and is down-r

79 t NPC patients had increased serum levels of leukemia inhibitory factor (LIF) and that higher LIF lev

80 vivo stem cell expansion are the addition of leukemia inhibitory factor (LIF) and the AC6.21 stromal

81 ences of nerve transection: the induction of leukemia inhibitory factor (LIF) and the reduction in th

82 We have found that leukemia inhibitory factor (LIF) and transforming growth

83 Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are IL-6 family members

84 onic stem cells in response to withdrawal of leukemia inhibitory factor (LIF) as a differentiation si

85 r identification of the IL-6 family cytokine leukemia inhibitory factor (LIF) as a serum predictor of

86 y upregulated with IL-6 pointed to STAT4 and leukemia inhibitory factor (LIF) as potentially linked.

87 ve determined the crystal structure of human leukemia inhibitory factor (LIF) bound to the cytokine b

88 Leukemia inhibitory factor (LIF) can influence developme

89 The receptor for leukemia inhibitory factor (LIF) consists of two polypep

90 Expression of leukemia inhibitory factor (LIF) cytokine mRNA, but not

91 is a new member of the interleukin 6 (IL-6)/leukemia inhibitory factor (LIF) cytokines, which activa

92 ress DeltaEGFR each also express IL-6 and/or leukemia inhibitory factor (LIF) cytokines.

93 nterleukin-6 (IL-6), oncostatin M (OSM), and leukemia inhibitory factor (LIF) direct the formation of

94 The cytokine leukemia inhibitory factor (LIF) drives self-renewal of

95 Leukemia inhibitory factor (LIF) expression in the uteru

96 Here we show that Leukemia Inhibitory Factor (LIF) expression is induced s

97 ibroblast pro-inflammatory programs inducing leukemia inhibitory factor (LIF) expression, supporting

98 hat five of the up-regulated miRNAs targeted leukemia inhibitory factor (LIF) expression.

99 es of the ciliary neurotrophic factor (CNTF)-leukemia inhibitory factor (LIF) family have been shown

100 Because leukemia inhibitory factor (LIF) has little or no effect

101 -2 mutation (Shp-2(Delta46-110)) demonstrate leukemia inhibitory factor (LIF) hypersensitivity and in

102 The role of the cytokine leukemia inhibitory factor (LIF) in axotomy-induced spro

103 Previous work has implicated the cytokine leukemia inhibitory factor (LIF) in cutaneous inflammati

104 PROK1 induces expression of leukemia inhibitory factor (LIF) in endometrial epitheli

105 We recently described the expression of leukemia inhibitory factor (LIF) in human fetal and muri

106 We have investigated the role of leukemia inhibitory factor (LIF) in postnatal neuronal d

107 re, we report an unexpected role of cytokine leukemia inhibitory factor (LIF) in protecting against G

108 At these doses, mRNA levels of leukemia inhibitory factor (LIF) increased.

109 Leukemia inhibitory factor (LIF) injections were given i

110 ch NPs expand after H-I and to determine how leukemia inhibitory factor (LIF) insufficiency affects t

111 Leukemia inhibitory factor (LIF) is a cytokine involved

112 Leukemia inhibitory factor (LIF) is a pleiotropic cytoki

113 Leukemia inhibitory factor (LIF) is a pleiotropic cytoki

114 Leukemia inhibitory factor (LIF) is a pleiotropic neuroi

115 Here we demonstrate that leukemia inhibitory factor (LIF) is a potent endogenous

116 The uterine expression of leukemia inhibitory factor (LIF) is essential for embryo

117 Leukemia inhibitory factor (LIF) is produced by a large

118 Leukemia inhibitory factor (LIF) is required, but not su

119 bes revealed that the gene encoding cytokine leukemia inhibitory factor (LIF) is robustly upregulated

120 We designed a transgene in which leukemia inhibitory factor (LIF) is under control of a l

121 erleukin-11 (IL-11), oncostatin M (OSM), and leukemia inhibitory factor (LIF) levels in patients with

122 tion (H3K27me3) to intergenic regions at the leukemia inhibitory factor (LIF) locus to drive increase

123 The cytokine leukemia inhibitory factor (LIF) modulates glial and neu

124 which ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) negatively regulate the

125 d the effects of overexpressing the cytokine leukemia inhibitory factor (LIF) on adult neurogenesis i

126 differentiation in response to withdrawal of leukemia inhibitory factor (LIF) or bone morphogenetic p

127 be induced in culture either by exposure to leukemia inhibitory factor (LIF) or by deprivation of ne

128 conditioned medium from mice lacking either leukemia inhibitory factor (LIF) or LIF and ciliary neur

129 stem (ES) cells in vitro requires exogenous leukemia inhibitory factor (LIF) or related cytokines.

130 erentiated pluripotent state is dependent on leukemia inhibitory factor (LIF) or related cytokines.

131 on-promoting conditions by the withdrawal of Leukemia Inhibitory Factor (LIF) or treatment with retin

132 Leukemia inhibitory factor (LIF) promotes differentiated

133 Leukemia inhibitory factor (LIF) promotes giant cell dif

134 y, CD8+ TRLs were reprogrammed to upregulate leukemia inhibitory factor (LIF) receptor, epidermal gro

135 eceptor complex, glycoprotein130 (gp130) and leukemia inhibitory factor (LIF) receptor, on cardiac fi

136 rophage chemoattractant protein-1 (MCP-1) or leukemia inhibitory factor (LIF) reduced this activity t

137 oid potential has indicated that exposure to leukemia inhibitory factor (LIF) results in the upregula

138 o exhibit increased Wnt expression, enhanced leukemia inhibitory factor (LIF) sensitivity, and reduce

139 Bone morphogenetic protein (BMP) and leukemia inhibitory factor (LIF) signaling both promote

140 ostatin M (OSM) and IL-27 levels but sparing leukemia inhibitory factor (LIF) signaling.

141 ded by Sort1) facilitates IL-6 secretion and leukemia inhibitory factor (LIF) signaling.

142 sets suggested interaction between Tet1 and leukemia inhibitory factor (LIF) signaling.

143 how here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulated Raf-1 activi

144 em (ES) cells, in which BMP4 synergizes with leukemia inhibitory factor (LIF) to maintain self-renewa

145 ations of basic fibroblast growth factor and leukemia inhibitory factor (LIF) to proliferate and unde

146 The addition of leukemia inhibitory factor (LIF) to purified CD34(+) thy

147 linked to the luciferase reporter, we showed leukemia inhibitory factor (LIF) to strongly potentiate

148 Previously, we reported that delivery of leukemia inhibitory factor (LIF) to the CNS stimulates t

149 gh it is generally accepted that addition of leukemia inhibitory factor (LIF) together with either se

150 Leukemia inhibitory factor (LIF) was critical for prolif

151 IL-6, sIL-6R, oncostatin M (OSM), IL-11, and leukemia inhibitory factor (LIF) was determined by rever

152 Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) were investigated to te

153 ESCs) initiated normal differentiation after leukemia inhibitory factor (LIF) withdrawal but, unlike

154 4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal.

155 heterogeneous onset of differentiation after leukemia inhibitory factor (LIF) withdrawal.

156 e embryo implantation arising from a lack of leukemia inhibitory factor (LIF), a critical factor of u

157 Leukemia inhibitory factor (LIF), a critical implantatio

158 n mice through transcriptional regulation of leukemia inhibitory factor (LIF), a cytokine crucial for

159 during the window of receptivity, including leukemia inhibitory factor (LIF), a cytokine produced sp

160 Importantly, treatment with leukemia inhibitory factor (LIF), a cytokine regulated b

161 Leukemia inhibitory factor (LIF), a multi-functional cyt

162 The mRNA for leukemia inhibitory factor (LIF), a neuroimmune signalin

163 igated the mannose phosphorylation status of leukemia inhibitory factor (LIF), a previously identifie

164 One of these candidates is leukemia inhibitory factor (LIF), a pro-inflammatory cyt

165 onstrated that the proinflammatory cytokine, leukemia inhibitory factor (LIF), affects the hypothalam

166 However, leukemia inhibitory factor (LIF), an IL-6 family cytokin

167 Leukemia inhibitory factor (LIF), an interleukin-6 famil

168 ell types and includes interleukin-6 (IL-6), leukemia inhibitory factor (LIF), and granulocyte-colony

169 tokines, including IL-6, oncostatin M (OSM), leukemia inhibitory factor (LIF), and IL-11, have fibrog

170 Oncostatin M (OSM), leukemia inhibitory factor (LIF), and interleukin-6 (IL-

171 erleukin 6 (IL-6) family of cytokines, IL-6, leukemia inhibitory factor (LIF), and oncostatin M, act

172 itors were identified as oncostatin M (OSM), leukemia inhibitory factor (LIF), and transforming growt

173 gp130-signaling cytokines, IL-6, IL-11, and leukemia inhibitory factor (LIF), as well as with up-reg

174 in G418 and engineered to express zebrafish leukemia inhibitory factor (Lif), basic fibroblast growt

175 F) and significantly lower concentrations of leukemia inhibitory factor (LIF), basic fibroblast growt

176 In the presence of recombinant leukemia inhibitory factor (LIF), CAFC cloning efficienc

177 Activating ligands of gp130, including leukemia inhibitory factor (LIF), can block differentiat

178 cells or by one of the following cytokines: leukemia inhibitory factor (LIF), ciliary neurotrophic f

179 d by an excess of antibodies to IL-6, IL-11, leukemia inhibitory factor (LIF), gp130, stromal cell de

180 kin (IL)-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor (LIF), granulocyte colonystim

181 creted multiple paracrine factors, including leukemia inhibitory factor (LIF), granulocyte-colony-sti

182 ting factor (G-CSF), stem cell factor (SCF), leukemia inhibitory factor (LIF), granulocyte-macrophage

183 uding ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF), induce the same phenot

184 ched with fibroblast growth factor 2 (FGF2), leukemia inhibitory factor (LIF), insulin-like growth fa

185 Because leukemia inhibitory factor (LIF), like SDF-1, is secrete

186 he interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and

187 e to interleukin-6 and -11 (IL-6 and IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), an

188 lly related proteins, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ci

189 6 (IL-6) family of cytokines, which includes Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ci

190 ocused on the activation of STATs 1 and 3 by leukemia inhibitory factor (LIF), oncostatin-M (OSM), an

191 members IL-11, IL-6, oncostatin M (OSM), and leukemia inhibitory factor (LIF), only OSM and LIF were

192 an undifferentiated state in the presence of leukemia inhibitory factor (LIF), or differentiate into

193 s for the receptors for growth hormone (GH), leukemia inhibitory factor (LIF), or interferon-gamma (I

194 ation of TNF, IL-1, and, to a lesser extent, leukemia inhibitory factor (LIF), produced a prompt and

195 IL-6), IL-11, IL-27, oncostatin M (OSM), and leukemia inhibitory factor (LIF), signal via the common

196 in vitro with media containing the cytokine leukemia inhibitory factor (LIF), which propagates the p

197 The cytokine leukemia inhibitory factor (LIF), which stimulates MEK5

198 during delayed implantation and in pregnant, leukemia inhibitory factor (LIF)-deficient mice with imp

199 nic sympathetic axotomy leads to a prolonged leukemia inhibitory factor (LIF)-dependent activation of

200 viral or episomal reprogramming), which uses leukemia inhibitory factor (LIF)-expressing SNL feeders,

201 Leukemia inhibitory factor (LIF)-induced activation of J

202 h factor (FGF)-ERK1/2 pathway, PI3K-AKT, the leukemia inhibitory factor (LIF)-JAK-STAT3 axis, Wnt-GSK

203 SOCS-3 is a novel intracellular regulator of leukemia inhibitory factor (LIF)-mediated proopiomelanoc

204 early points of differentiation, conducting leukemia inhibitory factor (LIF)-stimulated biochemical

205 ty in axons that is mediated by the cytokine leukemia inhibitory factor (LIF).

206 ignals for self-renewal are generated by the leukemia inhibitory factor (LIF).

207 with both epidermal growth factor (EGF) and leukemia inhibitory factor (LIF).

208 s and was identified by mass spectrometry as leukemia inhibitory factor (LIF).

209 ing intermediates following stimulation with leukemia inhibitory factor (LIF).

210 ophy and antiapoptotic phenotypes induced by leukemia inhibitory factor (LIF).

211 c stem (ES) cells downstream of the cytokine leukemia inhibitory factor (LIF).

212 quencing of one such factor identified it as leukemia inhibitory factor (LIF).

213 by ciliary neurotrophic factor (CNTF) or by leukemia inhibitory factor (LIF).

214 an undifferentiated state in the presence of leukemia inhibitory factor (LIF).

215 to the differentiation suppressing effect of leukemia inhibitory factor (LIF).

216 ukin-6, interleukin-11, cardiotrophin-1, and leukemia inhibitory factor (LIF).

217 rleukin (IL)-3, IL-6, c-kit ligand (KL), and leukemia inhibitory factor (LIF).

218 FOXA2-dependent GE-expressed genes, such as leukemia inhibitory factor (LIF).

219 ugh transcriptional up-regulation of uterine leukemia inhibitory factor (LIF).

220 leukin-6 (IL6) but also the related cytokine leukemia inhibitory factor (LIF).

221 but not at Thr308, in NRVMs stimulated with leukemia inhibitory factor (LIF).

222 renewal and alleviates their requirement for leukemia inhibitory factor (LIF).

223 r pluripotency by the supplementation of the leukemia inhibitory factor (LIF).

224 autocrine/paracrine pathway mediated by the leukemia inhibitory factor (LIF)/JAK/STAT pathway.

225 yer of ES cell aggregates independent of the leukemia inhibitory factor (LIF)/STAT3 pathway, it is la

226 ncy, which may occur in conjunction with the leukemia inhibitory factor (LIF)/Stat3 pathway.

227 Moreover, it provides a mechanism for how leukemia inhibitory factor (LIF)/STAT3 signaling reaches

228 Both cell types secreted leukemia inhibitory factor (Lif); however, whereas Stat3

229 d full-length globular proteins [mCherry and leukemia inhibitory factor (LIF)].

230 Leukemia-inhibitory factor (LIF) is a member of the inte

231 oRG cells express leukemia-inhibitory factor (LIF) receptors during neurog

232 TGF-beta plus EGF synergistically increased leukemia-inhibitory factor (LIF), additively increased I

233 related cytokines (i.e., oncostatin M [OSM], leukemia inhibitory factor [LIF], and IL-11).

234 Here, we report that four other cytokines (leukemia inhibitory factor [LIF], oncostatin M [OSM], in

235 tiated when cultured in the presence of LIF (leukemia inhibitory factor), little metabolism of exogen

236 In the absence of leukemia inhibitory factor, mouse ES cells give rise to

237 cultured in standard conditions (serum plus leukemia inhibitory factor) or ground-state conditions,

238 Leukemia inhibitory factor plays a major role in the ute

239 ther as a homodimer or as a heterodimer with Leukemia Inhibitory Factor Receptor (LIF-R).

240 gnal using heterodimers of gp130 with either leukemia inhibitory factor receptor (LIFR) (type I) or o

241 receptor complexes, glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR) alpha and gp1

242 described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130.

243 studies and clinical validation, we identify leukemia inhibitory factor receptor (LIFR) as a breast c

244 ed a placenta-specific enhancer in the human leukemia inhibitory factor receptor (LIFR) gene and now

245 Knockout of the leukemia inhibitory factor receptor (LIFR) gene results

246 ytokine family and signals through the gp130/leukemia inhibitory factor receptor (LIFR) heterodimer.

247 Leukemia inhibitory factor receptor (LIFR) promotes a do

248 n of epidermal growth factor receptor (EGFR)-leukemia inhibitory factor receptor (LIFR) signaling ind

249 igodendrocyte survival through activation of leukemia inhibitory factor receptor (LIFR) signaling is

250 ophic factor receptor alpha (CNTFRalpha) and leukemia inhibitory factor receptor (LIFR) was studied i

251 ectedly, messenger RNA and protein levels of leukemia inhibitory factor receptor (LIFR), a subunit of

252 oprotein 130 (gp130) heterodimerization with Leukemia Inhibitory Factor receptor (LIFR), type II OSM

253 HSCs express the leukemia inhibitory factor receptor (LIFR), which promot

254 ocyte cell surface, but failed to detect the leukemia inhibitory factor receptor (LIFR).

255 beta-receptors glycoprotein 130 (gp130) and leukemia inhibitory factor receptor (LIFR).

256 ndowed with dual activity toward FXR and the leukemia inhibitory factor receptor (LIFR).

257 th induction by OSM depends on both types I [leukemia inhibitory factor receptor (LIFR)] and II [OSM

258 rious cytoplasmic domains of either gp130 or leukemia inhibitory factor receptor alpha (LIFR) were us

259 The cytokine receptor subunits gp130, leukemia inhibitory factor receptor alpha (LIFRalpha), a

260 s marked early on by their downregulation of leukemia inhibitory factor receptor and was promoted by

261 link between the PTEN-Akt-FOXO axis and the leukemia inhibitory factor receptor beta (LIFRbeta)-STAT

262 phosphorylation of glycoprotein 130 (gp130), leukemia inhibitory factor receptor beta, and signal tra

263 ressive effect by directly targeting p63 and leukemia inhibitory factor receptor in RMS cells, which

264 cal and genetic manipulations indicated that leukemia inhibitory factor receptor signaling was indisp

265 was caused by placental defect with enhanced leukemia inhibitory factor receptor signaling.

266 Similarly, a leukemia inhibitory factor receptor subunit beta (LIFRbe

267 array of cytokines and express the LIFRbeta (leukemia inhibitory factor receptor) chain on their surf

268 We further demonstrate that one of these, leukemia inhibitory factor receptor, can initiate functi

269 opment, including GATA4, c-kit receptor, and leukemia inhibitory factor receptor.

270 cluded adiponectin, lumican, plasminogen and leukemia inhibitory factor receptor.

271 of granulocyte colony-stimulating factor and leukemia inhibitory factor receptors, which are normally

272 identify TFE3 and TFEB as cell type-specific leukemia inhibitory factor-responsive activators of E-ca

273 newal of embryonal stem cells in response to leukemia inhibitory factor signaling and for proliferati

274 They are dependent on leukemia inhibitory factor signaling for maintenance of

275 by the bone morphogenetic protein (BMP) and leukemia inhibitory factor signaling pathways and the ex

276 rocal relationship between PPARdelta-AKT and leukemia inhibitory factor-STAT3 signaling pathways serv

277 Shp2 deficiency leads to upregulation of leukemia inhibitory factor-stimulated phosphatidylinosit

278 (6)A depletion by Mettl3 knock-down in serum/leukemia inhibitory factor supports both pluripotency ma

279 of mouse ES cells by removal of the cytokine leukemia inhibitory factor, there is a global increase i

280 te inflammatory markers (IL-8, oncostatin M, leukemia inhibitory factor, TNF-a, IL-10, and IL-6).

281 We conclude that LIGHT overrides Leukemia inhibitory factor to induce ES cell differentia

282 rgy with host ciliary neurotrophic factor or leukemia inhibitory factor to promote neuronal survival

283 biquitously when cultured in the presence of leukemia inhibitory factor to suppress differentiation.

284 Ciliary neurotrophic factor and leukemia inhibitory factor, two cytokines critical to th

285 g hematopoietic lineages after withdrawal of leukemia inhibitory factor, using in vitro colony format

286 the fundamental role of fibroblast-secreted leukemia inhibitory factor was assessed by using small i

287 Although no change in leukemia inhibitory factor was observed throughout the d

288 actor alpha, interleukin 1 (IL-1), IL-6, and leukemia inhibitory factor, was markedly enhanced during

289 Levels of oncostatin M (OSM) and leukemia inhibitory factor were analyzed in patients wit

290 Two cytokines, interleukin-6 and leukemia inhibitory factor, which can induce phosphoryla

291 When PI3K/AKT1 signaling declines following leukemia inhibitory factor withdrawal, active GSK3beta a

292 f Cdk2ap1 in mESCs resulted in abrogation of leukemia inhibitory factor withdrawal-induced differenti

293 pression by osteoblasts of interleukin-6 and leukemia inhibitory factor without affecting the 16 othe